Tocilizumab-Atlizumab Overview

Introduction of Tocilizumab

Tocilizumab, also known as atlizumab, is a recombinant humanized, anti-human monoclonal antibody (mAb) of the immunoglobulin G1κ subclass directed against soluble and membrane-bound interleukin-6 (IL-6) receptor (IL-6R) which plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was developed by Hoffmann-La Roche and Chugai. It is marketed in the European Union (EU) under the trade name RoActemra and in the United States, Canada, Australia, and Japan as Actemra. Tocilizumab was first approved in 2005 as an orphan drug in Japan for the treatment of Castleman’s disease, a rare lymphoproliferative disease involving expansion of plasma cell numbers. Tocilizumab is now licensed in the EU for use alone or in combination with disease-modifying anti-rheumatic drugs (DMARDs) to treat adult patients with moderate to severely active rheumatoid arthritis (RA), children over 2 y of age with the systemic form of juvenile idiopathic arthritis (sJIA) or children over 2 y of age with the polyarticular form of juvenile idiopathic arthritis (pJIA). It has also been studied as a treatment of other conditions such as Crohn’s disease, systemic lupus erythematosus (SLE), Takayasu arteritis (TA), giant cell arteritis (GCA) polymyalgia rheumatica (PMR) and refractory adult-onset Still disease, but has not yet received licenses in these indications.

Mechanism of Action of Tocilizumab

IL-6 is a multifunctional cytokine that plays an important role in both acute and chronic inflammatory responses. Consequently, the dysregulated or persistent production of IL-6 can lead to the development of inflammatory disorders. Elevated levels of IL-6 in serum, synovial fluid, and various tissues have been correlated with disease activity in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), Castleman’s disease, systemic sclerosis (SSc), giant cell arteritis (GCA), adult-onset Still’s disease (AOSD), familial Mediterranean fever (FMF), Schnitzler’s syndrome, polychondritis, and amyloidosis. Tocilizumab targets the IL-6 receptor subunit alpha (IL-6Rα), and its mechanism of action has been described in detail in previous reviews. Briefly, Tocilizumab targets both membrane-bound and soluble IL-6Rα, which prevents the binding of IL-6 to both the IL-6R and the signal transducer glycoprotein 130 complex and results in turn in inhibition of the downstream classic signaling and trans-signaling cascades involving the Janus-activated kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Through this mechanism, Tocilizumab decreases the circulating levels of neutrophils, neutrophil infiltration into inflamed joints, circulation of myeloid dendritic cells, monocyte levels, serum macrophage migration inhibitory factor levels, and levels of T helper 17 (Th17) cells, while increasing regulatory T cells. Tocilizumab also induces regulatory B-cell expansion, decreases B-cell hyperactivity, and decreases the number of peripheral memory B cells.

Mechanism of action of tocilizumab Fig.1 Mechanism of action of tocilizumab

Clinical Projects of Tocilizumab*

NCT ID Status Conditions Lead Sponsor Update Time
NCT03554161 Recruiting Behcet Syndrome, Uveitis Wenjie Zheng June 13, 2018
NCT01717170 Active, not recruiting Intermediate Uveitis, Posterior Uveitis, Pan-uveitis University of Nebraska October 30, 2012
NCT01752335 Active, not recruiting Rheumatoid Arthritis Hospital Universitario de Canarias December 19, 2012
NCT03533101 Recruiting Cytokine Release Syndrome, Stem Cell Transplant Complications Hospital Universitario Dr. Jose E. Gonzalez May 22, 2018
NCT02043548 Recruiting Dermatomyositis, Polymyositis University of Pittsburgh January 23, 2014
NCT02908217 Recruiting Polymyalgia Rheumatica University Hospital, Brest September 20, 2016
NCT03244709 Recruiting Giant Cell Arteritis Hospital of Prato August 9, 2017
NCT02007239 Recruiting Hemophagocytic Lymphohistiocytosis Children's Hospital of Philadelphia December 10, 2013
NCT02477059 Recruiting Hand Osteoarthritis Assistance Publique - Hôpitaux de Paris June 22, 2015
NCT03263715 Recruiting Polymyalgia Rheumatica Medical University of Vienna August 28, 2017
NCT02874573 Recruiting Schizophrenia, Psychotic Disorders Brian Miller August 22, 2016
NCT02101333 Recruiting TAKAYASU ARTERITIS Assistance Publique - Hôpitaux de Paris April 2, 2014
NCT01441063 Recruiting Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia National Cancer Institute (NCI) September 27, 2011
NCT02765074 Recruiting Rheumatoid Arthritis Centre Hospitalier Régional d'Orléans May 6, 2016
NCT03446209 Recruiting Familial Mediterranean Fever University Hospital Tuebingen February 26, 2018
NCT02660528 Recruiting Major Depressive Disorder Brigham and Women's Hospital January 21, 2016
NCT03353259 Recruiting Chronic Subdural Hematoma Oslo University Hospital November 27, 2017
NCT02108600 Recruiting Late Complication From Kidney Transplant University of California, San Francisco April 9, 2014
NCT03046381 Recruiting Schnitzler's Syndrome Karoline Krause February 8, 2017
NCT02293837 Active, not recruiting Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D National Institute of Allergy and Infectious Diseases (NIAID) November 18, 2014
NCT03350633 Recruiting Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica Tianjin Medical University General Hospital November 22, 2017
NCT01557374 Active, not recruiting Rheumatoid Arthritis Assistance Publique - Hôpitaux de Paris March 19, 2012
NCT02963402 Recruiting Arthritis,Rheumatoid Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau November 15, 2016
NCT03588936 Not yet recruiting Multiple Myeloma, Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes Medical College of Wisconsin July 17, 2018
NCT03227419 Not yet recruiting Arthritis, Rheumatoid Lille Catholic University July 24, 2017
NCT03301883 Recruiting Juvenile Idiopathic Arthritis Hoffmann-La Roche October 4, 2017
NCT03062579 Active, not recruiting Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica, Devic's Disease Fu-Dong Shi February 23, 2017
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center March 11, 2015
NCT03291457 Recruiting Rheumatoid Arthritis Hoffmann-La Roche September 25, 2017
NCT03215407 Not yet recruiting Rheumatoid Arthritis of Knee Chinese PLA General Hospital July 12, 2017
NCT02608112 Active, not recruiting Rheumatoid Arthritis Hoffmann-La Roche November 18, 2015
NCT02511067 Not yet recruiting Diabetic Macular Edema University of Nebraska July 29, 2015
NCT02906371 Recruiting Lymphoblastic Leukemia, Acute, Childhood University of Pennsylvania September 20, 2016
NCT02837146 Recruiting Rheumatoid Arthritis Maria Stoenoiu July 19, 2016
NCT02353780 Recruiting Rheumatoid Arthritis (RA) Dr. Larry W. Moreland February 3, 2015
NCT02402686 Active, not recruiting Rheumatoid Arthritis Hoffmann-La Roche March 30, 2015
NCT03135171 Recruiting Breast Cancer University of Michigan Cancer Center May 1, 2017
NCT02453256 Active, not recruiting Systemic Sclerosis Hoffmann-La Roche May 25, 2015
NCT02929251 Recruiting Uveitis, Biotherapy Assistance Publique - Hôpitaux de Paris October 11, 2016
NCT02767557 Recruiting Unresectable Pancreatic Carcinoma Herlev Hospital May 10, 2016
NCT03202368 Recruiting Giant Cell Arteritis Hoffmann-La Roche June 28, 2017
NCT02251860 Active, not recruiting Rheumatoid Arthritis Hoffmann-La Roche September 29, 2014
NCT02616328 Recruiting Rheumatoid Arthritis Hoffmann-La Roche November 26, 2015
NCT01791153 Active, not recruiting Giant Cell Arteritis Hoffmann-La Roche February 13, 2013
NCT02165345 Active, not recruiting Juvenile Idiopathic Arthritis Hoffmann-La Roche June 17, 2014
NCT02206035 Active, not recruiting Hematopoietic Stem Cell Transplantation William R. Drobyski, MD August 1, 2014
NCT01734382 Recruiting Juvenile Idiopathic Arthritis Hoffmann-La Roche November 27, 2012
NCT03155347 Recruiting Rheumatoid Arthritis Hoffmann-La Roche May 16, 2017
NCT01194401 Active, not recruiting Rheumatoid Arthritis Hoffmann-La Roche September 3, 2010
NCT02336048 Active, not recruiting B-Cell Chronic Lymphocytic Leukemia Hoffmann-La Roche January 12, 2015
NCT02648035 Active, not recruiting Rheumatoid Arthritis Hoffmann-La Roche January 6, 2016
NCT02659150 Enrolling by invitation Rheumatoid Arthritis Massachusetts General Hospital January 20, 2016
NCT03434730 Recruiting Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia Memorial Sloan Kettering Cancer Center February 15, 2018
NCT03606876 Recruiting Rheumatoid Arthritis Bio-Thera Solutions July 31, 2018
NCT03522012 Recruiting Pharmacokinetics Mycenax Biotech Inc. May 10, 2018
NCT03100253 Recruiting Rheumatoid Arthritis Mario Negri Institute for Pharmacological Research April 4, 2017
NCT03112213 Active, not recruiting Rheumatoid Arthritis Hoffmann-La Roche April 13, 2017
NCT03282851 Recruiting Healthy Merck KGaA September 14, 2017
NCT03507348 Not yet recruiting End-stage Renal Disease, Kidney Transplantation, Hla-incompatible Kidney Transplant Candidates University Hospital, Grenoble April 25, 2018
NCT03004703 Recruiting Coronary Disease, Myocardial Infarction Oslo University Hospital December 29, 2016
NCT02049437 Active, not recruiting HIV Infections Case Western Reserve University January 30, 2014
NCT03440892 Recruiting Rheumatoid Arthritis Vastra Gotaland Region February 21, 2018

Approved Drugs of Tocilizumab**

INN (trade name) Therapeutic area Dose Strength Route Company Marketing start Market
Actemra Rheumatoid Arthritis Concentrate for solution 20 mg/mL Intravenous infusion Genentech January 08, 2010 Tocilizumab-Atlizumab Overview
Actemra Systemic Juvenile Idiopathic Arthritis (SJIA) Concentrate for solution 20 mg/mL Intravenous infusion Genentech April 15, 2011 Tocilizumab-Atlizumab Overview
Actemra Polyarticular Juvenile Idiopathic Arthritis (PJIA) Concentrate for solution 20 mg/mL Intravenous infusion Genentech April 29, 2013 Tocilizumab-Atlizumab Overview
Actemra Giant Cell Arteritis (GCA) Concentrate for solution 20 mg/mL Intravenous infusion Genentech May 22, 2017 Tocilizumab-Atlizumab Overview
Actemra Cytokine Release Syndrome (CRS) Concentrate for solution 20 mg/mL Intravenous infusion Genentech August 30, 2017 Tocilizumab-Atlizumab Overview
Actemra Rheumatoid Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Polyarticular Juvenile Idiopathic Arthritis (PJIA) Solution for injection 162 mg/ 0.9 mL Subcutaneous Genentech September 23, 2016 Tocilizumab-Atlizumab Overview
Actemra Giant Cell Arteritis (GCA) Solution for injection 162 mg/ 0.9 mL Subcutaneous Genentech May 22, 2017 Tocilizumab-Atlizumab Overview
Actemra Cytokine Release Syndrome (CRS Solution for injection 162 mg/ 0.9 mL Subcutaneous Genentech March 22, 2018 Tocilizumab-Atlizumab Overview
RoActemra Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid Concentrate for solution 20 mg/mL Intravenous infusion Roche Registration GmbH January 16, 2009 Tocilizumab-Atlizumab Overview
Actemra Rheumatoid Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Polyarticular Juvenile Idiopathic Arthritis (PJIA) Concentrate for solution 20 mg/mL Intravenous infusion Hoffmann-La Roche Limited May 26, 2010 Tocilizumab-Atlizumab Overview
Actemra Rheumatoid Arthritis, Giant Cell Arteritis (GCA) Solution for injection 162 mg/ 0.9 mL Subcutaneous Hoffmann-La Roche Limited May 30, 2014 Tocilizumab-Atlizumab Overview
Actemra Rheumatoid Arthritis Concentrate for solution 20 mg/mL Intravenous infusion Roche Products Pty Ltd May 21, 2009 Tocilizumab-Atlizumab Overview
Actemra Rheumatoid Arthritis Concentrate for solution 20 mg/mL Intravenous infusion Chugai Pharmaceutical Co., Ltd. April 16, 2008 Tocilizumab-Atlizumab Overview
Actemra Rheumatoid Arthritis Solution for injection 162 mg/ 0.9 mL Subcutaneous Roche Products Pty Ltd January 21, 2016 Tocilizumab-Atlizumab Overview
Actemra Rheumatoid Arthritis Solution for injection 162 mg/ 0.9 mL Subcutaneous Chugai Pharmaceutical Co., Ltd. April 16, 2008 Tocilizumab-Atlizumab Overview

What We Provide

Therapeutic Antibody

We provide high-quality for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Tocilizumab

** Information presented in the table were collected from the following websites:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125472
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000955/human_med_001042.jsp
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83535
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90943
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/6399421A1
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/6399421G1
http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=149404
http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=234034

Send Inquiry

  • Verification code
    Click image to refresh the verification code.
© 2007 - 2020 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart